Last reviewed · How we verify
CLDM 1% gel
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acne vulgaris, Bacterial skin infections.
At a glance
| Generic name | CLDM 1% gel |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Lincosamide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin works by binding to the bacterial 50S ribosomal subunit and inhibiting peptide bond formation, thereby preventing bacterial protein synthesis. This bacteriostatic action is effective against a broad range of gram-positive and anaerobic bacteria. The 1% gel formulation is designed for topical application to treat acne and other skin infections.
Approved indications
- Acne vulgaris
- Bacterial skin infections
Common side effects
- Dryness
- Erythema
- Peeling
- Oiliness
Key clinical trials
- DUAC® Early Onset Efficacy Study in Japanese Subjects (PHASE4)
- Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects (PHASE3)
- Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |